Earnings Momentum: Pfizer delivered second-quarter results that exceeded expectations, posting revenue of $15.03 billion and raising full-year guidance. Social media commentary centers on how core product sales helped counterbalance fading COVID-related revenue. Observers note multiple recent EPS beats as a key point of focus.
Vaccine Advancement: The company secured validation from European regulators for its Lyme disease vaccine candidate, setting the stage for a formal review. Discussions highlight this as a potential new growth avenue outside traditional portfolios. Market participants track the progress closely amid broader pharma developments.
Global Market Dynamics: Pfizer is positioning itself in China's expanding obesity treatment space alongside major competitors through targeted patient education efforts. Social media analysis emphasizes evolving communication tactics to reach consumers effectively. The intensifying competition underscores shifting industry strategies in high-potential regions.
Note: This discussion summary was generated from an AI condensation of post data.
Pfizer Insider Trading Activity
Pfizer insiders have traded $PFE stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PFE stock by insiders over the last 6 months:
- ALBERT BOURLA (Chairman & CEO) purchased 38,000 shares for an estimated $1,000,920
- RONALD E BLAYLOCK purchased 39,231 shares for an estimated $998,821
- MORTIMER J BUCKLEY purchased 37,632 shares for an estimated $960,368
- JENNIFER B. DAMICO (SVP & Controller) has made 0 purchases and 2 sales selling 5,278 shares for an estimated $134,661.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Pfizer Revenue
Pfizer had revenues of $15B in Q2 2026. This is an increase of 2.6% from the same period in the prior year.
You can track PFE financials on Quiver Quantitative's PFE stock page.
You can access data on PFE stock through the Quiver Quantitative API.
Pfizer Congressional Stock Trading
Members of Congress have traded $PFE stock 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PFE stock by members of Congress over the last 6 months:
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 06/08.
- SENATOR ALAN ARMSTRONG sold up to $100,000 on 03/24.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 03/13.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Pfizer Hedge Fund Activity
We have seen 1,315 institutional investors add shares of Pfizer stock to their portfolio, and 1,577 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM added 208,976,273 shares (+2320.6%) to their portfolio in Q2 2026, for an estimated $5,032,148,653
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 52,548,228 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,265,361,330
- BLACKROCK, INC. added 31,412,883 shares (+6.3%) to their portfolio in Q2 2026, for an estimated $756,422,222
- JPMORGAN CHASE & CO added 23,010,244 shares (+inf%) to their portfolio in Q2 2026, for an estimated $554,086,675
- WELLINGTON MANAGEMENT GROUP LLP removed 22,090,883 shares (-44.3%) from their portfolio in Q2 2026, for an estimated $531,948,462
- PACER ADVISORS, INC. added 16,793,903 shares (+inf%) to their portfolio in Q2 2026, for an estimated $404,397,184
- MARSHALL WACE, LLP removed 15,280,392 shares (-95.0%) from their portfolio in Q2 2026, for an estimated $367,951,839
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Pfizer Government Contracts
We have seen $1,121,856 of award payments to $PFE over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PFIZER VACCINES STORAGE AND ROTATION CONTRACT: $410,203
- 4571812561!PROCARDIA XL 30 MG TABLET 100S: $24,729
- 4569494415!PROCARDIA XL 30 MG TABLET 100S: $24,723
- 4571590545!NALOXONE 0.4 MG/ML VIALML: $22,620
- 4571408600!PROCARDIA XL 30 MG TABLET 100S: $14,837
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Pfizer Price Targets
Multiple analysts have issued price targets for $PFE recently. We have seen 11 analysts offer price targets for $PFE in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $28.0 on 07/08/2026
- Rajesh Kumar from HSBC set a target price of $28.0 on 07/06/2026
- Carter Gould from Cantor Fitzgerald set a target price of $27.0 on 07/06/2026
- Trung Huynh from RBC Capital set a target price of $25.0 on 06/10/2026
- Geoff Meacham from Citigroup set a target price of $27.0 on 04/29/2026
- Jin Zhang from CICC set a target price of $33.0 on 04/16/2026
- Michael Yee from UBS set a target price of $27.0 on 04/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
